BNT162b2SA

BNT162b2SA is an mRNA-based COVID-19 vaccine candidate developed by Pfizer and BioNTech. It is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes the full-length spike protein of SARS-CoV-2, specifically targeting the Beta (B.1.351) variant originally identified in South Africa[5][3]. The mechanism of action involves delivery of mRNA encoding the prefusion-stabilized spike protein into host cells, leading to expression of the antigen and subsequent induction of both innate and adaptive immune responses against SARS-CoV-2[1][8]. BNT162b2SA was evaluated as a booster or primary series in clinical trials for its safety and immunogenicity compared to BNT162b2[3][5].